All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Details

Target
GPC3

Targeting Cell Type
T cell

Targeting Diseases
hepatocellular carcinoma

Generation
Second

Vector Name
pCDCAR1

Vector Length
~8kb

Vector Type
Lentiviral vector

Receptor Construction
scFv-4-1BB-CD3ζ

Discription of Signaling Cassetes
41BB
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigennonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
CD3ζ
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

Customize Your CAR Products

Published Data

Complete CAR data Funcs

Fig.9 CAR-GPC3 expansion in peripheral blood of patients administered with CAR-GPC3 T cells.

CAR Construction : Y035 scfv-CD28-CD3ζ

Fig.9 CAR-GPC3 expansion in peripheral blood of patients administered with CAR-GPC3 T cells.

GPC3 CAR copies in peripheral blood rapidly increased to their peak at within one week post-infusion and then decreased gradually on each cycle.

Sun, Hongwei, et al. "Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report." Frontiers in immunology 13 (2022): 963031. Distributed under Open Access license CC BY 4.0, without modification.

Complete CAR data Funcs

Fig.10 TNF-a secretion in peripheral blood of patients administered with CAR-GPC3 T cells.

CAR Construction : Y035 scfv-CD28-CD3ζ

Fig.10 TNF-a secretion in peripheral blood of patients administered with CAR-GPC3 T cells.

Cytokine tumor necrosis factor-126 α (TNF-α) were elevated and reached their peaks at 3 days after each cycle of CAR T-cell 127 infusion, and then dropped to normal level after about 2 weeks.

Complete CAR data Funcs

Fig.11 IFN-γ secretion in peripheral blood of patients administered with CAR-GPC3 T cells.

CAR Construction : Y035 scfv-CD28-CD3ζ

Fig.11 IFN-γ secretion in peripheral blood of patients administered with CAR-GPC3 T cells.

Cytokine interferon-γ (IFN-γ) were elevated and reached their peaks at 3 days after each cycle of CAR T-cell 127 infusion, and then dropped to normal level after about 2 weeks.

Complete CAR data Funcs

Fig.12 IL-6 secretion in peripheral blood of patients administered with CAR-GPC3 T cells.

CAR Construction : Y035 scfv-CD28-CD3ζ

Fig.12 IL-6 secretion in peripheral blood of patients administered with CAR-GPC3 T cells.

Cytokine interleukin-6 (IL-6) were elevated and reached their peaks at 3 days after each cycle of CAR T-cell 127 infusion, and then dropped to normal level after about 2 weeks.

Complete CAR data Funcs

Fig.13 IL-10 secretion in peripheral blood of patients administered with CAR-GPC3 T cells.

CAR Construction : Y035 scfv-CD28-CD3ζ

Fig.13 IL-10 secretion in peripheral blood of patients administered with CAR-GPC3 T cells.

cytokine interleukin-10 (IL-10) were elevated and reached their peaks at 3 days after each cycle of CAR T-cell 127 infusion, and then dropped to normal level after about 2 weeks.

Complete CAR data Funcs

Fig.14 IL-15 secretion in peripheral blood of patients administered with CAR-GPC3 T cells.

CAR Construction : Y035 scfv-CD28-CD3ζ

Fig.14 IL-15 secretion in peripheral blood of patients administered with CAR-GPC3 T cells.

Cytokine interleukin-15 (IL-15) were elevated and reached their peaks at 3 days after each cycle of CAR T-cell 127 infusion, and then dropped to normal level after about 2 weeks.

More Published Data More Published Data

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.